Literature DB >> 10518370

Expressing estimators of expected quality adjusted survival as functions of Nelson-Aalen estimators.

Y Huang1, T A Louis.   

Abstract

Quality adjusted survival has been increasingly advocated in clinical trials to be assessed as a synthesis of survival and quality of life. We investigate nonparametric estimation of its expectation for a general multistate process with incomplete follow-up data. Upon establishing a representation of expected quality adjusted survival through marginal distributions of a set of defined events, we propose two estimators for expected quality adjusted survival. Expressed as functions of Nelson-Aalen estimators, the two estimators are strongly consistent and asymptotically normal. We derive their asymptotic variances and propose sample-based variance estimates, along with evaluation of asymptotic relative efficiency. Monte Carlo studies show that these estimation procedures perform well for practical sample sizes. We illustrate the methods using data from a national, multicenter AIDS clinical trial.

Entities:  

Mesh:

Year:  1999        PMID: 10518370     DOI: 10.1023/a:1009657629713

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  5 in total

1.  Estimating medical costs from incomplete follow-up data.

Authors:  D Y Lin; E J Feuer; R Etzioni; Y Wax
Journal:  Biometrics       Date:  1997-06       Impact factor: 2.571

2.  Estimation of expected quality adjusted survival by cross-sectional survey.

Authors:  J S Hwang; J Y Tsauo; J D Wang
Journal:  Stat Med       Date:  1996-01-15       Impact factor: 2.373

3.  Statistical analysis of quality of life data in cancer clinical trials.

Authors:  M Olschewski; M Schumacher
Journal:  Stat Med       Date:  1990-07       Impact factor: 2.373

Review 4.  Quality adjusted survival analysis.

Authors:  P P Glasziou; R J Simes; R D Gelber
Journal:  Stat Med       Date:  1990-11       Impact factor: 2.373

5.  Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  L D Saravolatz; D L Winslow; G Collins; J S Hodges; C Pettinelli; D S Stein; N Markowitz; R Reves; M O Loveless; L Crane; M Thompson; D Abrams
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

  5 in total
  3 in total

1.  Nonparametric Benefit-Risk Assessment Using Marker Process in the Presence of a Terminal Event.

Authors:  Yifei Sun; Chiung-Yu Huang; Mei-Cheng Wang
Journal:  J Am Stat Assoc       Date:  2017-04-12       Impact factor: 5.033

2.  A semi-Markov multistate model for estimation of the mean quality-adjusted survival for non-progressive processes.

Authors:  Gisela Tunes-da-Silva; Antonio C Pedroso-de-Lima; Pranab K Sen
Journal:  Lifetime Data Anal       Date:  2008-12-10       Impact factor: 1.588

3.  Regression analysis of mean quality-adjusted survival time based on pseudo-observations.

Authors:  G Tunes-da-Silva; J P Klein
Journal:  Stat Med       Date:  2009-03-30       Impact factor: 2.373

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.